KR920002164A - 연속 방출성 약학 조성물 - Google Patents

연속 방출성 약학 조성물 Download PDF

Info

Publication number
KR920002164A
KR920002164A KR1019910012589A KR910012589A KR920002164A KR 920002164 A KR920002164 A KR 920002164A KR 1019910012589 A KR1019910012589 A KR 1019910012589A KR 910012589 A KR910012589 A KR 910012589A KR 920002164 A KR920002164 A KR 920002164A
Authority
KR
South Korea
Prior art keywords
csf
ser
pharmaceutical composition
human
polypeptide
Prior art date
Application number
KR1019910012589A
Other languages
English (en)
Inventor
캠블 로저
팀즈 데이비드
제임스 윌킨슨 안토니
Original Assignee
수잔 제인 젠틀
임페리알 케미칼 인더스트리즈 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909016138A external-priority patent/GB9016138D0/en
Priority claimed from GB909018414A external-priority patent/GB9018414D0/en
Priority claimed from GB909018415A external-priority patent/GB9018415D0/en
Priority claimed from GB909018417A external-priority patent/GB9018417D0/en
Priority claimed from GB909018416A external-priority patent/GB9018416D0/en
Priority claimed from GB909018418A external-priority patent/GB9018418D0/en
Application filed by 수잔 제인 젠틀, 임페리알 케미칼 인더스트리즈 피엘씨 filed Critical 수잔 제인 젠틀
Publication of KR920002164A publication Critical patent/KR920002164A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

내용 없음

Description

연속 방출성 약학 조성물.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 참고에 5에 언급된 167bp 단편의 튜클레오티드 서열.
제2도는 인체(hu)G-CSF의 천연의 아미노산 서열과 대응 뉴클레오 티드 서열 및 제한부위를 나타내며.
제3도는 (Ser 17, 27)hu G-CSF의 아미노산 서열과 대응 뉴클레오 리드 서열 및 제한부위를 나타낸다.

Claims (20)

  1. 조성물 성분중 산에 안정한 생리적 활성 물질을 생리적 수성환경내로 연속방출하기 위한 약학 조성물에 있어서, 상기 활성물질은 수용성 중합체에 공유결합된 폴리펩티드로서, 소정의 사용기간동안 조성물이 처한 조건하에서 거의 가수분해되지 않으며, 상기 조성물은, i)생리적 수성 환경에 놓였을때, 상기 플리 펩티드를 상기 생리적 수성 환경에 연속방출함으로써, 적어도 일주일 동안 거의 단일상의 방출양상을 제공하거나, ii)상기 폴리펩티드를 두 가지 연속상으로 방출하는데, 즉 그 첫번째 상은 표며으로부터 확산방출하는 것이고, 두번째 상은 조성물성분의 분해시 방출하는 것으로서, 상기 확산상과 분해 유도상은 시간상 겹치며, 적어도 일주일의 기간동안 폴리펩티드를 방출하는 것을 특징으로 하며, 또는 iii)조성물 성분이 분해되어, 거의 모든 폴리펩티드가 생리적 수성환경내로 방출될 때까지, 적어도 일주일 동안 연속적으로 물을 흡수하여 거의 단일상의 물 흡수 양상을 제공하는 것을 특징으로 하는, 조성물 성분으로 부터 산안정성의 생리적 활성물질이 생리적 수성환경으로 연속 방출되는 약학 조성물.
  2. 제1항에 있어서, 생리적 활성물질 1분자가 폴리펩티드 3000 내지 8000Da 분자량당 수숑성 중합체 1분자 이상을 포함하는 것을 특징으로 하는 약학 조성물.
  3. 제1항 또는 제2항에 있어서, 상기 폴리펩티드가 천연발생의 G-CSF의 생물학적 특징을 적어도 하나 갖는 것을 특징으로 하는 약학 조성물.
  4. 제3항에 있어서, 상기 폴리펩티드가 천연 발생의 G-CSF의 생물학적 특징을 적어도 하나 지니며 5mg/㎖에 적어도 35%에 용액 안정성을 지니는 천연성 발생 G-CSF의 유도체이며, 상기 유도체는 천연 서열의 적어도 Cys17이 Ser17잔기로 대체되었으며 Asp27잔기로 대체된 것을 특징으로 하는 약학 조성물.
  5. 제4항에 있어서, 상기 폴리펩티드가 a)천연서열의 Glu11이 Arg11잔기로 대체된 변형체, b)천연서열의 Leu15가 Glu15잔기로 대체된 변형체, c)천연서열의 Lys23이 Arg23잔기로 대체된 변형체, d)천연서열의 Gly26이 Ala26잔기로 대체된 변형체, e)천연서열의 Gly28이 Ala28잔기로 데체된 변형체, f)천연서열의 Ala30이 Lys30또는 Arg30잔기로 대체된 변형체, g)천열서열의 Lgs34가 Arg34잔기로 데체된 변형체, h)천연서열의 Lys49가 Lys49잔기로 데체된 변형체, i)천연서열의 Pro44가 Ala44잔기로 대체된 변형체, j)천연서열이 Leu49가 Lys49잔기에 의해 대체된 변형체, k)천연서열의 Gly51가 Ala51잔기에 의해 대체된 변형체 l)천연서열의 Pro55이 Ser55잔기에 의해 대체된 변형체 m)천연서열의 Trp58이 Lys58잔기에 의해 대체된 변형체, n)천연서열의 Pro60이 Ser60잔기에 의해 대체된 변형체, o)천연서열의 Pro65가 Ser65잔기에 의해 대체된 변형체, q)천연서열이 Thr115가 Ser115잔기에 의해 대체된 변형체, r)천연서열의 Thr116이 Ser116잔기에 의해 대체된 변형체, s)천연서열의 Tyr165가 Arg165잔기에 의해 대체된 변형체, 중에서 선택된 변형체를 적어도 하나 더 포함하는 것을 특징으로 하는 약학 조성물.
  6. 제4항 또는 제5항에 있어서, 상기 폴리펩티드가 i)[Agr11, Ser17,27,60,65]인체 G-CSF, ii)[GlU15, Ser17,27,Ala26,28,Lys30]인체 G-CSF, iii)[Agr11, Glu15, Ser17,8,27,60,65,Ala26,28,Lys30]인체 G-CSF, iv)[Art11,40,Ser17,27,60,65]인체 G-CSF, v)[Arg11,23, Ser17,27,60,65]인체 G-CSF, vi)[Arg11,165, Glu15,Ser17,27,60,65, Ala26,28, Lys30,58]인체 G-CSF, vii)[Arg11, Glu15,111, Ser17,27,65,115,116, Ala26,28, Lys30]인체 G-CSF, viii)[Glu15, Ser17,27, Ala26,28, Lys30인체 G-CSF, and ix)[Arg1, Thr3, Tyr4, Arg5,11, Ser17,27,60,65]인체 -G-CSF, x)[Ser17,27,60,65]인체 G-CSF, 및 xi)[Arg11, Ser17,27,65]인체 G-CSF, xii)[Ser17,27,65]인체 G-CSF 중에서 선택되는 것을 특징으로 하는 약학 조성물.
  7. 제1항 또는 제2항에 있어서, 상기 폴리펩티드가 G-CSF 인체 칼시토닌, 인터루킨-2, 인터페론 및 인체성장 호르몬중에서 선택되는 것을 특징으로 하는 약학조성물.
  8. 제1항 내지 제7항중 어느 한 항에서, 수용성 중합체가 폴리에틸렌 글리콜 또는 폴리프로필렌 글리콜 단일 중합체, 폴리옥시에틸화 폴리올 또는 폴리비닐 알코올 중에서 선택되며, 이중 상기 단일 중합체가 알킬기로 한 말단이 치환되거나 비치환된 것을 특징으로 하는 약학 조성물.
  9. 제8항에 있어서, 상기 수용성 중합체가 비치환된 폴리에틸렌글리콜, 모노메틸 폴리에틸렌글리콜 및 폴리옥시 에틸화 글리세롤 중에서 선택되는 것을 특징으로 하는 약학 조성물.
  10. 제8항 또는 제9항에 있어서, 상기 수용성 중합체가 분자량이 1,000 내지 15,000인 것을 특징으로 하는 약학 조성물.
  11. 제1항 내지 제6항과 제8항 내지 제10항 중 어느 한항에 잇어서, 생리학적 활성물질이 예비서열 메티오닌이 존재하거나 도는 부재하는, 모노메틸 폴리에틸렌글리콜에 결합된 [Arg11, Ser17,27,60,65]인체 G-CSF이며, 상기 모노메틸 폴리에틸렌글리콜의 분자량이 2000 내지 5000인 것을 특징으로 하는 약학 조성물.
  12. 유기용매중에 조성물의 성분과 생리학적 활성물질을 용해시키거나 유기성 또는 수성 매체중에서 상기 조성물의 성분과 생리학적 활성물질을 균일하게 분산시킨후, 건조시키고 동물체내에 이식 또는 삽입하기에 적당한 조성물로 제형화하는 것을 포함하는 제1항 내지 제11항중 어느 한 항의 약학조성물의 제조방법.
  13. 조성물 성분이 폴리락티드를 포함하며, 생리학적 활성 물질을 25% 몰 이상의 젖산 유닛과 75% 몰 이하의 글리콜산 유닛으로 구성되는 상기 폴리락티드를 포함하는 매트릭스에 함입시키는 단계와 상기 조성물성분과 활성물질의 고형 혼합물을 완전히 용융시킴으로써 조성물성분과 생리학적 활성 물질을 균일하게 혼합하는 단계을 더 포함하는 것을 특징으로 하는, 제1항 내지 제11항중 어느 한항의 약학조성물의 제조방법.
  14. 제1항 내지 제11항중 어느 한항의 약학 조성물의 제조시 수용성 중합체에 공유결합된 폴리펩티드를 포함하는 것을 특징으로 하는 생리학적 활성물질의 사용방법.
  15. 제1항 내지 제11항중 어느 한항의 약학 조성물을 포유류에 투여함으로써, 수용성중합체에 공유결합된 폴리펩티드의 유효량을 전달시키며, 상기 폴리펩티드는 천연발생의 G-CSF의 생물학적 특징중 적어도 하나늘 갖는 것을 특징으로 하는 포유류의 조혈증(haematopoietic)을 치료하는 방법.
  16. 제1항 내지 제11항중 어느 한항의 약학조성물을 포유류에 투여함으로써 수용성 중합체에 공유결합된 폴리펩티드의 유효량을 전달시키며, 상기 폴리펩티드는 천연 발생의 G-CSF의 생물학적 특징중 적어도 하나를 갖는 것을 특징으로 하는 포유류의 백혈구 세포의 증식을 억제하는 방법.
  17. 제1항 내지 제11항중 어느 한항의 약학 조성물을 인체에 투여함으로써 수용성 중합체에 결합된 인체 칼시토닌의 유효량을 전달하는 것을 포함하는 다공증 또는 파겟츠(Paget's) 질환의 환자를 치료하는 방법.
  18. 제1항 내지 제11항중 어느 한항의 약학조성물을 포유류에 투여함으로써 수용성 중합체에 결합된 인터루킨-2의 유효량을 전달하는 것을 포함하는 포유류의 신생종양 또는 면역결핍증을 치효하는 방법.
  19. 제1항 내지 제11항중 어느 한항의 약학조성물을 포유류에 투여함으로써 수용성 중합체에 결합된 인터페론의 유효량을 전달하는 것을 포함하는 포유류의 신생종양이나 바이러스 질환을 치료하는 방법.
  20. 제1항 내지 제11항중 어느 한항의 약학조성물을 인체에 투여함으로써 수용성 중합체에 결하된 인체 증식호르몬의 유효량을 전달하는 것을 포함하는 인체의 성장을 촉진하는방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910012589A 1990-07-23 1991-07-22 연속 방출성 약학 조성물 KR920002164A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB9016138.1 1990-07-23
GB909016138A GB9016138D0 (en) 1990-07-23 1990-07-23 Continuous release pharmaceutical compositions
GB909018414A GB9018414D0 (en) 1990-08-23 1990-08-23 Continuous release pharmaceutical compositions
GB909018415A GB9018415D0 (en) 1990-08-23 1990-08-23 Continuous release pharmaceutical compositions
GB9018417.7 1990-08-23
GB909018417A GB9018417D0 (en) 1990-08-23 1990-08-23 Continuous release pharmaceutical compositions
GB9018418.5 1990-08-23
GB9018416.9 1990-08-23
GB9018414.4 1990-08-23
GB909018416A GB9018416D0 (en) 1990-08-23 1990-08-23 Continuous release pharmaceutical compositions
GB9018415.1 1990-08-23
GB909018418A GB9018418D0 (en) 1990-08-23 1990-08-23 Continuous release pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR920002164A true KR920002164A (ko) 1992-02-28

Family

ID=27547094

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910012589A KR920002164A (ko) 1990-07-23 1991-07-22 연속 방출성 약학 조성물

Country Status (18)

Country Link
US (2) US5320840A (ko)
EP (1) EP0473268B1 (ko)
JP (1) JP3188292B2 (ko)
KR (1) KR920002164A (ko)
AT (1) ATE251641T1 (ko)
AU (1) AU655187B2 (ko)
BG (1) BG94861A (ko)
CA (1) CA2047540A1 (ko)
CS (1) CS228591A3 (ko)
DE (1) DE69133324T2 (ko)
FI (1) FI913410A (ko)
GB (1) GB2246295B (ko)
HU (1) HUT60632A (ko)
IE (1) IE912365A1 (ko)
IL (1) IL98831A0 (ko)
NZ (1) NZ238889A (ko)
PT (1) PT98410A (ko)
ZW (1) ZW9391A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100815114B1 (ko) * 2005-02-21 2008-03-20 주식회사 엘지생명과학 단백질 약물의 지속 방출 조성물

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US20050181976A1 (en) * 1993-05-10 2005-08-18 Ekwuribe Nnochiri N. Amphiphilic oligomers
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
WO1995021629A1 (en) * 1994-02-08 1995-08-17 Amgen Inc. Oral delivery of chemically modified proteins
EP0744409B9 (en) * 1994-02-23 2009-08-19 Kyowa Hakko Kogyo Co., Ltd Platelet growth accelerator
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
GEP20002180B (en) * 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
JPH10506280A (ja) * 1994-09-23 1998-06-23 ディー． フィンケルスタイン，シドニー 形態的遺伝子型識別法
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5576197A (en) * 1995-04-07 1996-11-19 Molecular Bio-Products Polymerase chain reaction container and methods of using the same
EP0832220A1 (en) * 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
FR2738827B1 (fr) * 1995-09-18 1997-10-17 Bio Merieux Detection des enterobacteries
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
CA2337661A1 (en) 2000-02-29 2001-08-29 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
US6716811B1 (en) * 2000-07-20 2004-04-06 Affymax, Inc. Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
GB0022877D0 (en) * 2000-09-18 2000-11-01 Isis Innovation Analogues
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
AU2001298061A1 (en) 2000-12-13 2003-07-09 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
WO2005004792A2 (en) * 2003-06-24 2005-01-20 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2003078461A1 (en) 2002-03-20 2003-09-25 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
CA2537158C (en) 2002-08-27 2014-07-22 Hirokazu Tamamura Cxcr4 antagonist and use thereof
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) * 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
AU2004229461A1 (en) 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Method for preparation of site-specific protein conjugates
US20070041937A1 (en) * 2003-08-22 2007-02-22 The Council Of The Queensland Institute Of Medical Research G-csf derivative for inducing immunological tolerance
EP2196210A1 (en) * 2003-10-24 2010-06-16 Nora, LLC A method for reducing the likelihood of preeclampsia in a subject in need thereof
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP1694363B1 (en) * 2003-12-16 2014-01-22 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
US20060088871A1 (en) * 2004-10-22 2006-04-27 Finkelstein Sydney D Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
ATE524509T1 (de) 2005-07-18 2011-09-15 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
US20080214480A1 (en) * 2005-07-22 2008-09-04 Trf Pharma, Inc. Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae
EP1984009B1 (en) * 2006-01-18 2012-10-24 Qps, Llc Pharmaceutical compositions with enhanced stability
US7678838B2 (en) * 2006-08-04 2010-03-16 University Of Memphis Research Foundation Nanothin polymer films with selective pores and method of use thereof
US7829155B1 (en) 2006-11-22 2010-11-09 The University Of Memphis Research Foundation Nanothin polymer coatings containing thiol and methods of use thereof
FR2909560B1 (fr) * 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique Gel d'acide hyaluronique pour injection intradermique
WO2008075369A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
US20110171168A1 (en) * 2008-05-13 2011-07-14 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
US10138283B2 (en) * 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010079340A2 (en) 2009-01-08 2010-07-15 Eisai R & D Management Co., Ltd. Assay
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
KR101719339B1 (ko) 2009-06-14 2017-03-23 바이오카인 테라퓨틱스 리미티드 혈소판 수준을 증가시키는 펩타이드 요법
AU2010280688A1 (en) 2009-08-05 2012-02-23 Allergan, Inc. Controlled release formulations of lipocalin muteins
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
GB0922438D0 (en) 2009-12-22 2010-02-03 Ucl Business Plc Agents having tissue generative activity
CN102906108B (zh) 2010-03-04 2016-01-20 菲尼克斯公司 用于无变性制备可溶性重组干扰素蛋白的方法
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
SI2637694T1 (sl) 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati dela IL-2 in polimera
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US9341628B2 (en) 2012-11-30 2016-05-17 Interpace Diagnostics Corporation Methods for measuring carcinoembryonic antigen
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
KR102231217B1 (ko) * 2015-09-24 2021-03-24 한미약품 주식회사 면역글로불린 단편의 특정 위치를 연결 부위로 이용한 단백질 결합체
KR101763644B1 (ko) * 2015-12-03 2017-08-02 윤안구 폐 생리대 수거함
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US10758329B1 (en) 2019-08-20 2020-09-01 Raymond L. Wright, III Hydrating mouth guard

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812443A (ko) * 1968-08-31 1970-03-03
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1338839C (en) * 1988-01-29 1997-01-14 Yoshio Sasaki Controlled release formulation
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5055555A (en) * 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100815114B1 (ko) * 2005-02-21 2008-03-20 주식회사 엘지생명과학 단백질 약물의 지속 방출 조성물

Also Published As

Publication number Publication date
ZW9391A1 (en) 1992-03-25
PT98410A (pt) 1992-06-30
HU912442D0 (en) 1991-12-30
FI913410A0 (fi) 1991-07-15
US5773581A (en) 1998-06-30
IE912365A1 (en) 1992-01-29
IL98831A0 (en) 1992-07-15
EP0473268A3 (en) 1992-09-16
CA2047540A1 (en) 1992-01-24
FI913410A (fi) 1992-01-24
EP0473268B1 (en) 2003-10-08
NZ238889A (en) 1993-08-26
AU8123891A (en) 1992-01-30
JP3188292B2 (ja) 2001-07-16
EP0473268A2 (en) 1992-03-04
ATE251641T1 (de) 2003-10-15
GB9115207D0 (en) 1991-08-28
BG94861A (en) 1994-03-24
GB2246295A (en) 1992-01-29
US5320840A (en) 1994-06-14
HUT60632A (en) 1992-10-28
CS228591A3 (en) 1992-03-18
GB2246295B (en) 1994-05-11
AU655187B2 (en) 1994-12-08
JPH0532559A (ja) 1993-02-09
DE69133324T2 (de) 2004-07-29
DE69133324D1 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
KR920002164A (ko) 연속 방출성 약학 조성물
EP0326151B1 (en) Improved controlled release formulation
US6376461B1 (en) Sustained-release preparation
AU769347B2 (en) Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents
KR100622796B1 (ko) 폴리올-ｉｆｎ-베타 공액체
KR100236771B1 (ko) 히아루론산을 이용한 약물의 서방성 미세입자 제형
EP1077070A3 (en) Oral drug delivery compositions
EP0922446A1 (en) Solution-phase site-specific preparation of GRF-PEG conjugates
EP0219076A2 (en) Sustained release composition
CH675968A5 (ko)
WO2000000222A9 (en) Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents
AU2004251456B2 (en) Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a PLGA matrix
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
JP2702729B2 (ja) 徐放性埋込剤
KR101585046B1 (ko) 경비 투여용 의약 조성물
KR100679925B1 (ko) 신규한 ５―플루오로우라실 좌제 조성물
JPH0694418B2 (ja) 長期徐放性製剤

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid